Drug Profile
Golnerminogene pradenovec
Alternative Names: ADgvEGR.TNF.11D; TNF-α gene therapy - GenVec; TNFerade; Tumour necrosis factor-alpha gene therapy - GenVecLatest Information Update: 29 Jun 2017
Price :
$50
*
At a glance
- Originator Asahi Kasei
- Developer GenVec; National Cancer Institute (USA)
- Class Antineoplastics; Cytokine genes; Gene therapies
- Mechanism of Action Gene transference; Tumour necrosis factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Colorectal cancer; Head and neck cancer; Malignant melanoma; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Sarcoma
Most Recent Events
- 16 Jun 2017 GenVec was acquired by Intrexon Corporation
- 04 Sep 2013 Golnerminogene pradenovec is available for licensing as of 04 Sep 2013. http://www.genvec.com/
- 02 Nov 2010 GenVec receives Qualifying Therapeutic Discovery Project grant from the US Government for Golnerminogene pradenovec development in Cancer